| Literature DB >> 35315522 |
Akarapon Watcharapalakorn1, Teera Poyomtip1, Patarakorn Tawonkasiwattanakun1.
Abstract
PURPOSE: Although studies have suggested that the coronavirus disease 2019 (COVID-19) outbreak increased myopia progression, they had different settings and analysis methods. This study compared myopia progression before and during the COVID-19 outbreak using meta-analysis.Entities:
Keywords: COVID-19; meta-analysis; myopia pandemic; optometrist; public health
Mesh:
Year: 2022 PMID: 35315522 PMCID: PMC9115422 DOI: 10.1111/opo.12976
Source DB: PubMed Journal: Ophthalmic Physiol Opt ISSN: 0275-5408 Impact factor: 3.992
FIGURE 1The selection process diagram to identify eligible studies following Preferred Reporting Items for Systematic Review and Meta‐Analysis (PRISMA)
General information on the included studies
| Study | Location | Time points | Age (years) | N | Pre‐COVID‐19 | During‐COVID‐19 | Measurement method | ||
| Baseline | Before‐COVID‐19 | During‐COVID‐19 | ΔMean SER in D (SD) | ΔMean SER in D (SD) | |||||
| Aslan et al. | Turkey | N/A | N/A | Aug‐20 | 8–17 | 115 | 0.54 (0.43) | 0.71 (0.46) | CA |
| Chang et al. | Zhejiang, China | Mar‐19 | Oct‐19 | May‐20 | 6–15 | 29 719 | 0.20 (0.99) | 0.50 (1.02) | NCA |
| Hu et al. | Guangdong, China | Nov‐18 | Nov‐19 | Nov‐20 | 6–7 | 1060 | 0.31 (0.46) | 0.67 (0.56) | CA |
| Ma et al. | Shanghai, China | Apr‐19 | Oct‐19 | May‐20 | 7–12 | 201 | 0.39 (0.58) | 0.98 (0.52) | CA |
| Ma et al. | Hebei, China | Jul‐19 | Jan‐20 | Aug‐20 | 8–10 | 208 | 0.33 (0.47) | 0.93 (0.65) | CA |
| Picotti et al. | Argentina | N/A | N/A | Sep‐20 | 5–18 | 115 | 0.44 (0.52) | 0.58 (0.53) | CA |
| Wang et al. | Shandong, China | Sep‐18 | Sep‐19 | Jun‐20 | 6–13 | 194 904 | 0.02 (1.55) | 0.17 (1.54) | NCP |
| Xu et al. | Zhejiang, China | Jun‐19 | Dec‐19 | Jun‐20 | 7–18 | 547 475 | 0.26 (0.37) | 0.39 (0.38) | NCA |
Abbreviations: CA, cycloplegic autorefraction; D, dioptre; N/A, not available; NCA, noncycloplegic autorefraction; NCP, noncycloplegic photoscreener; SD, standard deviation; SER, spherical equivalent refraction.
The durations have to be at least or assumed to be 8 months between each of the three different examinations.
Calculated difference in mean SER or SD.
The sample during COVID‐19 was 575,597.
This was the pre‐COVID‐19 sample; the sample during COVID‐19 was 1054.
Quality assessment using Newcastle‐Ottawa Scale of cross‐sectional, case–control and cohort study
| Study | Cross‐sectional study | Case–control study | Cohort study | Total (10) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selection | Comparability | Outcome | Selection | Comparability | Outcome | Selection | Comparability | Outcome | ||||||||||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | ||
| Aslan et al. | ★ | ★★ | ★ | ★★ | ★ | 7 | ||||||||||||||||||
| Wang et al. | ★ | ★ | ★ | ★ | ★ | ★★ | ★ | 8 | ||||||||||||||||
| Hu et al. | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 | |||||||||||||||
| Chang et al. | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 | |||||||||||||||
| Ma et al. | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 | ||||||||||||||||
| Ma et al. | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 | |||||||||||||||
| Picotti et al. | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 | ||||||||||||||||
| Xu et al. | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 | ||||||||||||||||
Cross‐sectional study: 1, representative of sample; 2, justified sample size; 3 non‐respondents; 4, ascertainment of exposure; 5, the subjects in different outcome groups are comparable, based on study design or analysis; 6, assessment of outcome; 7, statistical test.
Case–control study: 1, is the case definition adequate; 2, representativeness of the cases; 3, selection of controls; 4, definition of controls; 5, comparability of cases and controls on the basis of the design or analysis; 6, ascertainment of exposure; 7, same method of ascertainment for cases and controls; 8, non‐response rate.
Cohort study: 1, representativeness of the exposed cohort; 2, selection of the non‐exposed cohort; 3, ascertainment of exposure; 4, demonstration that outcome of Interest was not present at start of study; 5, comparability of cohorts on the basis of the design or analysis; 6, assessment of outcome; 7, was follow‐up long enough for outcomes to occur; 8, adequacy of follow up of cohorts.
Duration of refractive measurement and annual myopia progression
| Study | Duration of refractive measurement (months) | Annualised progression in D (SD) | ||
|---|---|---|---|---|
| Pre‐COVID‐19 | During‐COVID‐19 | Pre‐COVID‐19 | During‐COVID‐19 | |
| Aslan et al. | 8 | 8 | 0.81 (0.65) | 1.07 (0.69) |
| Chang et al. | 8 | 8 | 0.30 (1.48) | 0.75 (1.53) |
| Hu et al. | 12 | 12 | 0.31 (0.46) | 0.67 (0.56) |
| Ma et al. | 7 | 7 | 0.67 (0.99) | 1.68 (0.89) |
| Ma et al. | 6 | 6 | 0.66 (0.94) | 1.86 (1.30) |
| Picotti et al. | 8 | 8 | 0.66 (0.78) | 0.87 (0.80) |
| Wang et al. | 12 | 9 | 0.02 (1.55) | 0.22 (2.05) |
| Xu et al. | 6 | 6 | 0.52 (0.74) | 0.78 (0.76) |
Abbreviations: D, dioptre; SD, standard deviation.
Duration of refractive measurement was estimated to be at least 8 months between each of the three different examinations.
FIGURE 2Meta‐analysis of the myopic shift in 773 797 individuals from eight studies. (a) Forest plot of mean difference in annual myopia progression showing the comparison before and during the COVID‐19 pandemic. The square's area was proportionate to study weight. The horizontal line indicates 95% CIs. The overall impact is shown as diamonds, with CIs at the lateral points. (b) Radial plot (c) Funnel plot with pseudo‐95% CIs. CI, confidence interval; MD, difference in mean; SE, standard error
Sensitivity analysis of included studies
| Omitted study | Mean difference in D (95% CI) |
|
|---|---|---|
| Aslan et al. | 0.43 [0.36–0.50] | <0.01 |
| Chang et al. | 0.38 [0.32–0.44] | <0.01 |
| Hu et al. | 0.43 [0.35–0.50] | <0.01 |
| Ma et al. | 0.36 [0.29–0.43] | <0.01 |
| Ma et al. | 0.36 [0.29–0.42] | <0.01 |
| Picotti et al. | 0.43 [0.36–0.50] | <0.01 |
| Wang et al. | 0.50 [0.38–0.62] | <0.01 |
| Xu et al. | 0.50 [0.36–0.65] | <0.01 |
Abbreviations: CI, confidence interval; D, dioptre; MD, mean difference.
FIGURE 3Subgroup analysis using (a) non‐cycloplegic and (b) cycloplegic measurement. Forest plot comparing myopia progression before and during the COVID‐19 pandemic. The square area was proportionate to study weight. The horizontal line indicates 95% CIs. The overall impact is shown as diamonds, with CIs at the lateral points. CI, confidence interval